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Abstract Inflammatory joint diseases such as rheumatoid
arthritis, as well as other rheumatic conditions, such as system-
ic lupus erythematosus (SLE) and ankylosing spondylitis,
comprise a heterogeneous group of joint disorders that are all
associated with extra-articular side effects, including bone loss
and fractures. The concept of osteoimmunology is based on
growing insights into the links between the immune system
and bone. The pathogenesis of osteoporosis in these patients is
multifactorial. We have, more or less as an example, described
this extensively for patients with SLE. High disease activity
(inflammation) and immobility are common factors that sub-
stantially increase fracture risk in these patients, on top of the
background fracture risk based on, among other factors, age,
body mass index, and gender. Although no fracture reduction
has been shown in intervention studies in patients with inflam-
matory rheumatic diseases, we present treatment options that
might be useful for clinicians who are treating these patients.
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Introduction
Osteoporosis-related fragility fractures represent one of the
most important complications that may occur in patients
with rheumatic diseases; obviously, these fractures may
contribute to an important decrease in quality of life. Dis-
ease activity (inflammation), immobility, and treatment with
glucocorticoids are the main factors that increase the risk of
osteoporotic fractures, on top of the background fracture
risk based on, among other factors, age, body mass index,
and gender (Fig. 1). Recent data in the field of osteoimmu-
nology, the cross-talk between cytokines and bone, have
elucidated that activated inflammatory cells at sites of in-
flammation produce a wide spectrum of cytokines that stim-
ulate local and generalized bone resorption, and that inhibit
(in rheumatoid arthritis [RA]) or stimulate (in ankylosing
spondylitis [AS]) bone formation. We discuss extensively
the complex pathogenesis of generalized bone loss in sys-
temic lupus erythematosus (SLE), followed by a description
of bone involvement in RA and, somewhat briefly, in AS.
Finally, treatment options are discussed.
Osteoporosis and Fractures in Systemic Lupus
Erythematosus
SLE is a chronic autoimmune disease that usually affects
women in their reproductive years. Over the past decades,
the survival of SLE patients has improved dramatically, and
the morbidity pattern has shown a shift toward long-term
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disease complications, including generalized osteoporosis
(fractures).
Osteopenia, defined as a T-score in the lumbar spine and/or
hips between −1 and −2.5, is demonstrated in 25 % to 74% of
SLE patients [1, 2]. Osteoporosis, a T-score less than −2.5, is
reported in 1.4 % to 68 % of patients [3, 4]. These wide
variations are probably related to differences in study design,
size, age, ethnicity, sex, disease severity, and medication use
between the investigated patients. The etiology of bone loss in
SLE is supposed to be multifactorial, including traditional risk
factors for osteoporosis such as old age and low body weight,
but also incorporates disease-related factors: inflammation,
metabolic factors, hormonal factors, serologic factors, and
medication-induced adverse effects [5•].
The traditional risk factors, age [6, 7], postmenopausal
status [5•, 6], low body weight [7], or low body mass index
[6–8], have all been recognized as independent risk factors
for osteoporosis in SLE.
The influence of gender on bone loss in SLE is unclear,
as the majority of studies investigated (almost) exclusively
female patients. In line with findings in the general popula-
tion, two studies in lupus patients showed that white [9] or
non-African Caribbean ethnicity [10] was a risk factor for
osteoporosis, while another study demonstrated reduced
bone mineral density (BMD) in African American women
with SLE compared with white patients after controlling for
clinical variables and after adjusting for glucocorticoid (GC)
use [11]. Smoking is not reported as a risk factor for oste-
oporosis in SLE [6, 8, 10] but has recently been identified as
a risk factor for osteoporotic fractures in a study from the
Hopkins Lupus Cohort [12].
Chronic systemic inflammation may contribute to bone
loss in SLE. In patients with active lupus, increased serum
levels of tumor necrosis factor (TNF) [13] and oxidized low-
density lipoprotein (LDL) [14] were demonstrated. Oxidized
lipids induce activation of T cells, which in turn induce in-
creased production of receptor activator of nuclear factor-κB
ligand (RANKL) and TNF. Both TNF and RANKL enhance
the maturation and activity of osteoclasts [13]. In addition,
oxidized LDL may negatively influence bone formation by
reducing osteoblast maturation [15]. In premenopausal wom-
en with recently diagnosed and untreated SLE, decreased
serum levels of osteocalcin (marker for bone formation) and
increased cross-links excretion in the urine (marker for bone
resorption) were demonstrated [16].
Until now, clinical studies have failed to demonstrate a
relationship between disease activity score and bone loss in
SLE [6, 8, 9, 17], which might be explained by the cross-
sectional design of these studies. However, low complement
C4 levels (a measure of active disease) were a predictor of
low spine BMD in the Hopkins Lupus Cohort [7]. More-
over, several studies reported an association between organ
damage and reduced BMD [6, 9, 17, 18]. Because organ
damage accumulates in patients with prolonged active dis-
ease, this finding suggests that disease activity negatively
influences BMD in SLE.
Although inflammation-induced lupus nephritis may oc-
cur in 50 % to 60 % of the SLE patients ever during the
disease course, only one study in older female SLE patients
reported an association between impaired renal function and
low BMD [6], probably related to the exclusion of patients
with renal failure in most of the studies.
Studies in SLE patients in different geographical regions
demonstrate an increased frequency of vitamin D deficiency
[19–21], a metabolic condition that induces bone loss.
Moreover, low 25-hydroxyvitamin D (25[OH]D) serum
levels were associated with low spine BMD in Dutch lupus
patients [8].
Fig. 1 Risk factors for
osteoporosis and fractures in
inflammatory rheumatic
diseases. AS ankylosing
spondylitis; BMI body mass
index; SLE systemic lupus
erythematosus
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Vitamin D status might be negatively influenced by sev-
eral factors in SLE: photosensitivity (leading to avoidance
of sun exposure) and use of sunscreens, dark skin pigment,
renal failure, GC use, and probably hydroxychloroquine
(HCQ) use. In SLE patients, an association between cumu-
lative GC use and low levels of both 25(OH)D and 1,25
(OH)2D has been reported [21].
The antimalarial HCQ, which is frequently used to
treat SLE, might impair vitamin D status, as this drug
is supposed to inhibit the conversion of 25(OH)D to 1,25
(OH)2D by inhibiting hydroxylase α1. A cross-sectional
study demonstrated reduced 1,25(OH)2D levels in HCQ-
treated SLE patients compared with nonusers [20]. How-
ever, another study reported higher 25(OH)D levels in
patients treated with HCQ [22]. In two cross-sectional
studies in female patients, HCQ use was associated with
higher BMD in the spine [2, 9] and hip [9]. Further
longitudinal studies in large groups of SLE patients as
well as in patients with other diseases treated with HCQ
are needed to unravel the relationship between HCQ use
and bone (metabolism).
Hormonal changes in patients with SLE may adversely
affect bone mass. SLE is characterized by a relatively high
estrogenic and low androgenic state, and a decrease in
dehydroepiandrosterone (DHEA) and an association be-
tween low DHEA sulfate levels and low BMD in SLE
patients was reported [23].
A study on the relationship between serologic factors and
BMD demonstrated that the presence of anti-Sm and the
absence of anti-Ro were associated with a higher spine
BMD [2].
GCs are frequently used in SLE for the treatment of
disease exacerbations or complications and play a dual role
with respect to bone mass. On one hand, GCs induce bone
loss, but on the other hand, they have a beneficial effect on
bone mass by suppressing inflammation. The several cross-
sectional studies on the relationship between GC use and
BMD in SLE have yielded conflicting results. However,
three of four small longitudinal studies performed showed
increased bone loss in all patients receiving GC treatment
[3], or exclusively in patients treated with more than 7.5 mg
prednisone daily [24, 25].
Because changes in BMD are usually not associated with
clinical signs and symptoms, fracture data are clinically
more relevant. In a population-based study in women with
SLE, the incidence of clinical fractures was nearly fivefold
increased compared with healthy controls [26]. Symptomat-
ic fractures are reported in 6 % to 12.5 % of the patients
because lupus diagnosis [7, 10, 26, 27] and age [7, 10, 26],
postmenopausal status [7], smoking [12], disease duration
[27], renal failure [12], Raynaud’s phenomenon [12], re-
duced BMD [10], and presence of lupus anticoagulant [12]
are identified as risk factors.
Moreover, GC treatment is associated with future osteo-
porotic fractures [7], and older age at lupus diagnosis and
duration of GC treatment are associated with time from
lupus diagnosis to fracture [26]. Prevalent vertebral fractures
are demonstrated in 20 % to 26.1 % of the SLE patients [8,
17, 28]. Age [17, 28], low BMD [17, 28], previous use of
intravenous methylprednisolone [8], male sex [8], and, sur-
prisingly, high body mass index [28] were associated with
vertebral fractures. Importantly, two studies demonstrated
normal BMD in 29 % to 35.8 % of the patients with one or
more vertebral fractures [17, 28], which illustrates the lim-
ited value of BMD measurement in the assessment of future
fracture risk.
Osteoporosis and Fractures in Rheumatoid Arthritis
RA is characterized by the presence of inflammatory syno-
vitis and the destruction of cartilage and bone. These bone
complications are very characteristic of RA and can be
divided into three different forms: periarticular bone loss
adjacent to the inflamed joints, bone erosions, and systemic
osteoporosis. Remarkably, the local and generalized bone
loss share common pathways: the RANKL/osteoprotegerin
(OPG) pathway [29]. The RANKL/OPG pathway is in-
volved in the regulation of bone resorption in RA by stim-
ulating the activation, differentiation, and proliferation of
osteoclasts by RANKL, with OPG acting as a decoy recep-
tor [30]. Recently, it has been elucidated that several inflam-
matory cytokines, such as TNF-α, interleukin (IL)-1, IL-6
and IL-17, upregulate RANKL, with subsequent activated
osteoclastogenesis [31•, 32••]. RANKL is expressed by
osteoblasts but also by activated T cells and B cells and
seems to be a critical factor for joint destruction in RA.
Interestingly, in a study in RA patients in which all patients
were treated with methotrexate (MTX), treatment with
denosumab, a monoclonal antibody against RANKL, versus
placebo, reduced joint damage [33]. When looking more in
detail, the erosion score was lower in both the 60-mg and
180-mg denosumab-treated patients, while the joint space
narrowing was unattached. Although there are some sugges-
tions that joint space narrowing is more closely related to
physical dysfunction, it is important to realize that nowa-
days, many RA patients are treated with the effective but
costly combination of MTX and a biological (eg, a TNF
blocker), and that the combination of high-dose MTX plus
denosumab could be an attractive alternative. However, this
should be investigated further.
The Wnt pathway is a regulatory pathway of osteoblast
activity. At the molecular level, the activation of the Wnt/B
catenin pathway is crucial for osteoblastic differentiation
[34, 35]. Two blockers of the Wnt-signaling pathway that
play an important role in RA are dickkopf-1 (Dkk-1) and
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sclerostin. TNF-α, for instance, can induce both sclerostin
and Dkk-1 [32••]. Garnero et al. [36] found in a study in
early RA that patients with Dkk-1 levels in the highest
quartile had a more than five times higher relative risk for
radiological progression than patients in the lowest quartile.
In another study in RA patients, RANKL/OPG was lower
than in healthy controls, while Dkk-1 and sclerostin were
higher. After treatment with anti–IL-6, OPG/RANKL in-
creased, Dkk-1 decreased, and sclerostin increased [37].
Xu and colleagues [38] investigated osteoimmunology in
the pathogenesis of osteoporosis in 64 hospitalized disease-
modifying antirheumatic drug (DMARD)-naive RA patients
and age- and sex-matched healthy controls. They found a
higher prevalence of osteoporosis (T-score<−2.5), increased
levels of RANKL, and decreased OPG levels in RA patients
compared with healthy controls. In fact, these data illustrate
the elevated bone resorption but also the reduced bone
formation in patients with inflammatory rheumatic diseases,
as has been reviewed by Schett et al. [39].
Even a small rise in the level of systemic inflammation
can precipitate bone loss and may lead to fractures [32••].
The prevalence of osteoporosis in RA is increased about
twofold compared with the general population: this was
among other findings shown in a study by Haugeberg et
al. [40], in which the prevalence of osteoporosis, defined as
a T-score less than −2.5 in females, was increased 2 times in
394 female RA patients compared with a reference popula-
tion [40]. Before the introduction of biologicals, a high bone
loss was observed in a longitudinal study in early RA: −2.4
% at the spine and −4.3 % at the hip [41]. In a subgroup
analysis, bone loss in both the spine and the hips was much
larger in those patients with high C-reactive protein (CRP)
levels (>20 mg/dL) than in those patients with low CRP
levels (<20 mg/dL) (eg, in the spine, −2.1 % vs 0.2 %,
respectively). The same was found in the lumbar spine for
patients with low functional capacity (Health Assessment
Questionnaire [HAQ] score >1) compared with patients
with a better HAQ score (<1) (−1.9 % vs −0.2 %, respec-
tively). Although bone loss was substantial in earlier stud-
ies, we have recently shown that treatment with anti-TNF
arrests BMD loss at the hip and the spine. In an open cohort
study of 102 RA patients from Norway and The Nether-
lands, all treated with infliximab, there was no bone loss at
the spine and hip after 1 year, while BMD in patients with a
European League Against Rheumatism (EULAR) good re-
sponse showed a favorable change in BMD compared with
patients not achieving such a response, indicating that ade-
quately suppressing the inflammation in RA is beneficial for
the prevention of generalized bone loss [42]. In the BEST
study, a similar result was shown. The BEST study is a
randomized controlled trial comparing four different treat-
ment strategies, including, among others, COBRA and
MTX/infliximab, in early RA patients striving for remission.
In all four groups, there was only moderate generalized bone
loss at 2 years at the hip and spine (−0.5 % to 1.0 %) [41]. In
addition, patients in remission had less bone loss than
patients with low or moderate disease activity (0 %, −2 %,
and −3 %, respectively) [42]. However, in both studies [43,
44], BMD of the hand measured by digital x-ray radio-
grammetry was not arrested but showed a significant de-
crease, indicating that anti-inflammatory treatment still
needs some improvement.
It is important to realize that not low bone mass, but
fractures are the clinically most relevant outcome. Earlier
studies have shown that patients with RA are also at an
increased risk of both vertebral and nonvertebral fractures
[45, 46]. In a large cohort study from the General Practice
Research Database, it was shown that the risk of osteopo-
rotic fractures in RA patients is increased 1.5-fold (1.4–1.6)
compared with healthy controls [47]. The most frequently
reported risk factors associated with osteoporosis in RA are
inflammation, immobility, corticosteroid use, and disease
duration, but traditional risk factors for osteoporosis (ie,
low BMD and previous fractures) also contribute to fracture
risk in RA [48••].
In a recent study, we showed that in a 5-year follow-up
study in female RA patients older than 50 years of age with
established disease, new nonvertebral fractures occurred in
16 % of patients, and a new radiological vertebral fracture
occurred in 19 % of the patients [49]. Compared with
historical controls, these frequencies are about 1.5 to 2 times
higher than expected. Recently, Amin and colleagues [50]
performed a retrospective cohort study in RA patients and
matched healthy controls. They found that the risk of oste-
oporotic fractures was particularly increased in younger RA
patients. In the whole group of female RA patients, the OR
for an osteoporotic fracture was 1.7 (95 % CI, 1.4–2.2), but
in the subgroup of female patients younger than 50 years of
age, an OR of 4.3 (95 % CI, 2.4–7.8) was found.
Osteoporosis and Fractures in Ankylosing Spondylitis
AS is a chronic inflammatory disease with an elevated risk
of vertebral fractures. More than 20 years ago, it was docu-
mented that vertebral fracture risk is six to seven times
higher than in healthy controls [51, 52]. In contrast, no data
are available that have documented an elevated nonvertebral
fracture rate in AS, which could be a true phenomenon, but
an elevated fracture risk could also be masked by an inad-
equate design or a lack of power of the studies. It is impor-
tant to realize that vertebral fractures in patients with AS are
often associated with neurological signs and symptoms [53].
What is the underlying mechanism for the elevated frac-
ture risk in AS? It is thought that it is probably a result of
bone loss and/or elevated rigidity of the spine. Indeed, in
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several cross-sectional studies, the markers of bone resorp-
tion, such as the pyridinolines but also RANKL, were upre-
gulated in cohorts of AS patients compared with healthy
controls [54, 55]. Studies on BMD show a different pattern:
in early AS, the BMD both at the spine and at the hips is
lower than in healthy controls, while in contrast, in later
stages, a further decrease in hip BMD can be found, whereas
in the lumbar spine, the BMD might be increased due to the
formation of syndesmophytes [56, 57]. Recent data suggest
a low BMD and a high prevalence of vertebral fractures,
even in patients with early spondyloarthropathies [58, 59].
As the bone loss in AS is related to inflammation, the proof
of the pudding is in the eating: when patients are adequately
treated with TNF-blocking agents, the usually occurring
bone loss can be arrested [60]. Another point is the debate
surrounding inflammation and syndesmophyte formation.
Maksymowych et al. [61] observed that lesions on MRI
predict syndesmophytes, while Schett [62] argued for an
independent development.
Prevention of fractures in patients with AS is relatively
simple in those with clinical risk factors for osteoporosis and
a low T-score (<−2.5)—in other words, when there is an
indication for anti-osteoporotic treatment irrespective of the
presence of AS. In AS patients with a BMD in the osteo-
penic range, treatment decisions are more complicated.
Prevention and Treatment of Osteoporosis
and Fractures in Patients with Rheumatoid Arthritis,
Systemic Lupus Erythematosus, and Ankylosing
Spondylitis
General lifestyle measures are important for all patients with
rheumatic diseases: an adequate calcium intake, prevention of
falls, adequate vitamin D levels, and prevention of immobili-
zation, if possible. Special attention must be paid to sufficient
serum 25(OH)D serum levels in SLE patients because of
photosensitivity. In addition, the prescription of adequate im-
munosuppressive medication to reduce inflammation-induced
bone loss is important, which has been documented in RA.
It is important to realize that the relative risk of fractures
is increased in all three patient groups, and thus, the absolute
fracture risk is particularly high in those patients with a high
background fracture risk (eg, postmenopausal women with
an inflammatory rheumatic disorder). Unfortunately, inter-
vention studies demonstrating the effectiveness of one of the
available anti-osteoporotic drugs (eg, bisphosphonates) for
fracture reduction in patients with RA, SLE, or AS have not
been performed yet. However, the effectiveness of several
anti-osteoporotic drugs (bisphosphonates, strontium rane-
late, selective estrogen receptor modulators, denosumab,
and teriparatide/PTH) has been clearly demonstrated in
postmenopausal women with primary osteoporosis, which
is a strong argument to prescribe these drugs in patients with
inflammatory rheumatic disorders, particularly in those with
high background fracture risk and moderate or high disease
activity. Bisphosphonates (alendronate, risedronate, and
zoledronate) are usually the first choice because they are
widely prescribed, generally safe, and effective, even in the
prevention of hip fractures, although there are some con-
cerns about long-term safety [63].
Bisphosphonates are recommended for the prevention
and treatment of GC-treated individuals without renal fail-
ure, but these drugs should not be prescribed to premeno-
pausal patients planning a pregnancy, as bisphosphonates
are associated with fetal abnormalities in animal studies
[64]. Bisphosphonates should only be prescribed to premen-
opausal patients with (high risk of) severe osteoporosis, who
have completed their families, or who have decided not to
become pregnant for several years. Another point is the use
of bisphosphonates during long-term use of GCs. Although
bisphosphonates are effective in the initial phase of treat-
ment, their use in long-term treatment can be criticized [65].
Denosumab, a monoclonal antibody against RANKL, is
an attractive new therapeutic agent for osteoporotic patients
with renal failure and for RA patients. Not only has an
increase in BMD of the spine and the hips been demonstrat-
ed in RA patients, but also a strong reduction in joint
erosions.
The situation is somewhat more complicated in patients
with AS, as local bone loss and local new bone formation
can be found in the same patient. Obviously, this makes it
more difficult to decide which drugs to prescribe; in other
words, collaborative studies elucidating the pathogenesis
and new intervention studies are urgently needed in these
patients.
Conclusions
Several, if not all, inflammatory rheumatic diseases might
be complicated by elevated bone loss and increased fracture
rate. We focus on RA, SLE, and AS because bone loss and
fracture rate are relatively adequately documented in these
diseases. Several factors play a role in the fracture rate in
these patients, varying from demographic factors such as
age and body mass index to immobility and high disease
activity. Recent data in the field of osteoimmunology, the
cross-talk between inflammatory cells and bone cells, have
provided some insight into the complex pathogenesis of
bone loss in systematic inflammatory diseases. Fundamental
studies have elucidated that the upregulated RANKL, with
subsequent activated osteoclastogenesis, is an important
determinant of bone loss in RA.
Clinical studies have demonstrated that adequate immu-
nosuppressive therapy (eg, according to the treat-to-target
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principle) prevents both local and generalized bone loss.
Thus, optimal treatment of the underlying condition is the
first step toward prevention of fractures in these patients (eg,
for RA, this has been documented for the use of TNF
blockers or combination therapy with conventional drugs).
Apart from that, a healthy lifestyle (calcium, vitamin D,
prevention of falls, and immobilization) is important; for
those patients with a low T-score, treatment with bisphosph-
onates or denosumab might be attractive.
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